"A study presented at ECO 2026 shows that significant weight loss using GLP-1 medications reduces risks of osteoarthritis, CKD, and sleep apnea. Patients who gained weight after starting treatment faced higher risks of these conditions. Approximately half of the patients discontinued GLP-1 treatment within one year. The study analyzed data from nearly 90,000 patients in the US."